Abstract
A series of phenyl alkyl ketone derivatives based phosphodiesterase 4 (PDE4) inhibitors was subjected to 2D Quantitative Structure–Activity Relationships (2D QSAR) and Hologram Quantitative Structure–Activity Relationship (HQSAR) studies. The dataset was divided into training and test sets by applying K-means clustering, and 2D QSAR models were established using stepwise linear regression analysis, replacement method and enhanced replacement methods. The models obtained demonstrated high correlation coefficient (R2=0.8374) and low standard deviation (S=0.4442). The robustness of models was confirmed using leave one out cross validation (R2 cv=0.7189), Y scrambling (R2=0.3640), and by test set prediction (R2 pred=0.6867). Topological, steric, electronic and electrotopological descriptors of phenyl alkyl ketone derivatives showed good correlation with the PDE4 inhibitory activity. HQSAR models were established using various fragment sizes, hologram lengths and fragment types. The top HQSAR model was justified by high R2 value of 0.973 and R2 cv value of 0.641. New molecules were designed based on these results and the activity was predicted using the established models.
Keywords: cAMP, cGMP, HQSAR, Phosphodiesterase, QSAR, Y scrambling.
Current Enzyme Inhibition
Title:Quantitative Structure Activity Relationship and Design of Phenyl Alkyl Ketone Derivatives as Inhibitors of Phosphodiesterase 4
Volume: 10 Issue: 1
Author(s): Anand Gaurav, Vertika Gautam and Ranjit Singh
Affiliation:
Keywords: cAMP, cGMP, HQSAR, Phosphodiesterase, QSAR, Y scrambling.
Abstract: A series of phenyl alkyl ketone derivatives based phosphodiesterase 4 (PDE4) inhibitors was subjected to 2D Quantitative Structure–Activity Relationships (2D QSAR) and Hologram Quantitative Structure–Activity Relationship (HQSAR) studies. The dataset was divided into training and test sets by applying K-means clustering, and 2D QSAR models were established using stepwise linear regression analysis, replacement method and enhanced replacement methods. The models obtained demonstrated high correlation coefficient (R2=0.8374) and low standard deviation (S=0.4442). The robustness of models was confirmed using leave one out cross validation (R2 cv=0.7189), Y scrambling (R2=0.3640), and by test set prediction (R2 pred=0.6867). Topological, steric, electronic and electrotopological descriptors of phenyl alkyl ketone derivatives showed good correlation with the PDE4 inhibitory activity. HQSAR models were established using various fragment sizes, hologram lengths and fragment types. The top HQSAR model was justified by high R2 value of 0.973 and R2 cv value of 0.641. New molecules were designed based on these results and the activity was predicted using the established models.
Export Options
About this article
Cite this article as:
Gaurav Anand, Gautam Vertika and Singh Ranjit, Quantitative Structure Activity Relationship and Design of Phenyl Alkyl Ketone Derivatives as Inhibitors of Phosphodiesterase 4, Current Enzyme Inhibition 2014; 10 (1) . https://dx.doi.org/10.2174/15734080113096660006
DOI https://dx.doi.org/10.2174/15734080113096660006 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mesenchymal Stem Cells for Treatment of CNS Injury
Current Neuropharmacology Induced Adaptive Resistance to Nitrooxidative Stress in the CNS: Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry Neurofibrillary Tangles and Senile Plaques in Alzheimers Brains are Associated with Reduced Capillary Expression of Vascular Endothelial Growth Factor and Endothelial Nitric Oxide Synthase
Current Neurovascular Research Anti-Cancer Effects of Citalopram on Hepatocellular Carcinoma Cells Occur via Cytochrome C Release and the Activation of NF-kB
Anti-Cancer Agents in Medicinal Chemistry A New Perspective of Cannabinoid 1 Receptor Antagonists: Approaches Toward Peripheral CB1R Blockers without Crossing the Blood-Brain Barrier
Current Topics in Medicinal Chemistry The Kinetics of Non-Synaptically Triggered Acute Excitotoxic Responses in the Central Nervous System Observed Using Intrinsic Optical Signals
CNS & Neurological Disorders - Drug Targets Involvement of IL-1R/TLR Signalling in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Molecular Medicine Adaptive Behavior in Williams-Beuren Syndrome, Down Syndrome, and Autism Spectrum Disorder
Current Psychiatry Reviews Preface
Current Pharmaceutical Design Recent Insights on the Medicinal Chemistry of Metal-Based Compounds: Hints for the Successful Drug Design
Current Medicinal Chemistry Clinically Relevant Pharmacokinetic Herb-drug Interactions in Antiretroviral Therapy
Current Drug Metabolism Interventions Against Sarcopenia in Older Persons
Current Pharmaceutical Design Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) The Tachykinergic System as Avenues for Drug Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma on Cirrhosis: State of the Art and Future Perspectives
Recent Patents on Anti-Cancer Drug Discovery Editorial [Hot Topic: Genome and Proteome Analyses of Autoimmune Diseases (Executive Editor: G. Neeck)]
Current Pharmaceutical Design Drug-Induced Pulmonary Hypertension in Newborns: A Review.
Current Vascular Pharmacology Towards More Efficient Glutathione Peroxidase Mimics: Substrate Recognition and Catalytic Group Assembly
Current Medicinal Chemistry Gender Differences in Metabolic Syndrome – A Key Research Issue
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Purine Nucleoside Analogues for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery